IBDTalk 2026 – 3rd edition – Focus on Ulcerative Colitis

The IBDTalk 2026 – 3rd edition offers a comprehensive scientific and educational update on the evolving landscape of Ulcerative Colitis (UC). 

The program bridges current standard care and next-generation therapeutic approaches, addressing key clinical challenges and the multidisciplinary management of complex UC scenarios, including the overlap between Irritable Bowel Syndrome (IBS) and Inflammatory Bowel Disease (IBD), as well as coexisting Spondyloarthritis (SPA).

The agenda provides a critical review of therapeutic strategies, examining the role of conventional agents (mesalazine, steroids) alongside the timing and real-life effectiveness of advanced therapies, with a specific focus on emerging biological mechanisms. 

Through plenary sessions, tandem talks, the interactive “InflamMaze” workgroups, and the Clinical Case Contest, the event fosters interaction, practical learning, and refinement of clinical decision-making regarding surgical timing, innovative trial designs, and disease management.

Overall, IBDTalk 2026 promotes high-level scientific exchange and fosters innovation, enhancing the adoption of effective clinical approaches and ultimately improving patient outcomes in UC.

Responsabili Scientifici

Alessandro Armuzzi

Professore Ordinario, Direttore della Scuola di Specializzazione in Malattie dell'Apparato Digerente, Humanitas University, Pieve Emanuele MI

Responsabile Unità Malattie Infiammatorie Croniche Intestinali, IRCCS Humanitas Research Hospital, Rozzano MI

Flavio Andrea Caprioli

Professore Associato di Gastroenterologia, Dipartimento di Fisiopatologia Medico-Chirurgica e dei Trapianti, Università degli Studi di Milano

Unità di Gastroenterologia ed Endoscopia, Fondazione IRCCS Cà Granda, Ospedale Policlinico, Milano

Ambrogio Orlando

Specialista in Gastroenterologia, Responsabile Unità Operativa

Semplice Dipartimentale Malattie Infiammatorie Croniche Intestinali,

AO Ospedali Riuniti "Villa Sofia-Cervello”, Palermo